SHMT2 Drives the Progression of Colorectal Cancer by Regulating UHRF1 Expression

Figure 5

SHMT2 regulates CRC cell progression in vivo and in vitro by targeting UHRF1. (a) Real-time PCR analysis of SHMT2 and UHRF1 expression levels in SW480 and SW620 cells transduced with shSHMT2 TET-ON virus. Beta-actin was used as a loading control. (b) Representative western blot image of SHMT2 and UHRF1 protein level in the shSHMT2 TET-ON SW480 and SW620 cells. Beta-actin was used as a loading control. (c) WB analysis of SHMT2 and UHRF1 expression level in SW480 and SW620 cells transduced with a retrovirus expressing UHRF1. (d) The proliferation of shSHMT2 TET-ON and UHRF1 overexpressed SW480 cells in the absence and presence of doxycycline was analyzed by a CCK8 assay. The cell numbers were analyzed every day for 6 days. (e) The percentage of cells in each phase was determined by flow cytometric analysis. (f) Representative colony-forming assay showing the effects of shSHMT2 TET-ON and UHRF1 overexpressed SW480 on the clonogenicity. (g) The in vivo tumors that developed after 10 days of treatment are shown in the images, as well as the tumor weights of the mice after treatment. SHMT2: serine hydroxymethyltransferase 2 (mitochondrial); CRC: colorectal cancer; sh: short hairpin RNA; UHR1: ubiquitin-like with PHD and ring finger domains 1. , , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)